Anti-Cancer Therapeutic Strategies Based on Hgf/Met, Epcam, and Tumor-Stromal Cross Talk Publisher



Barzaman K^{1, 2} ; Vafaei R^{1, 3} ; Samadi M¹ ; Kazemi MH^{1, 4} ; Hosseinzadeh A¹ ; Merikhian P¹ ; Moradikalbolandi S¹ ; Eisavand MR¹ ; Dinvari H¹ ; Farahmand L¹ Show Affiliations
Source: Cancer Cell International Published:2022

Abstract

As an intelligent disease, tumors apply several pathways to evade the immune system. It can use alternative routes to bypass intracellular signaling pathways, such as nuclear factor-κB (NF-κB), Wnt, and mitogen-activated protein (MAP)/phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR). Therefore, these mechanisms lead to therapeutic resistance in cancer. Also, these pathways play important roles in the proliferation, survival, migration, and invasion of cells. In most cancers, these signaling pathways are overactivated, caused by mutation, overexpression, etc. Since numerous molecules share these signaling pathways, the identification of key molecules is crucial to achieve favorable consequences in cancer therapy. One of the key molecules is the mesenchymal-epithelial transition factor (MET; c-Met) and its ligand hepatocyte growth factor (HGF). Another molecule is the epithelial cell adhesion molecule (EpCAM), which its binding is hemophilic. Although both of them are involved in many physiologic processes (especially in embryonic stages), in some cancers, they are overexpressed on epithelial cells. Since they share intracellular pathways, targeting them simultaneously may inhibit substitute pathways that tumor uses to evade the immune system and resistant to therapeutic agents. © 2022, The Author(s).